From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

Committee on Infectious Diseases - Pediatrics, 2009 - pubmed.ncbi.nlm.nih.gov
Palivizumab was licensed in June 1998 by the US Food and Drug Administration for
prevention of serious lower respiratory tract disease caused by respiratory syncytial virus
(RSV) in pediatric patients who are at increased risk of severe disease. Safety and efficacy
have been established for infants born at or before 35 weeks' gestation with or without
chronic lung disease of prematurity and for infants and children with hemodynamically
significant heart disease. The American Academy of Pediatrics (AAP) published a policy …

Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

Committee on Infectious Diseases - Pediatrics, 2009 - publications.aap.org
This Policy Statement was retired January 2013. Palivizumab was licensed in June 1998 by
the US Food and Drug Administration for prevention of serious lower respiratory tract
disease caused by respiratory syncytial virus (RSV) in pediatric patients who are at
increased risk of severe disease. Safety and efficacy have been established for infants born
at or before 35 weeks' gestation with or without chronic lung disease of prematurity and for
infants and children with hemodynamically significant heart disease. The American …